Cleanzine: your weekly cleaning and hygiene industry newsletter 25th April 2024 Issue no. 1111

Your industry news - first

The original and best - for over 20 years!

We strongly recommend viewing Cleanzine full size in your web browser. Click our masthead above to visit our website version.

FDA limits on antibacterial healthcare ingredients could put patients and employees at risk

An advisory committee to the Food & Drug Administration in the US has been told that unreasonable FDA restrictions on healthcare use of safe and effective antibacterial ingredients could jeopardise the safety of patients and healthcare workers alike.

In a presentation to the FDA's Non-prescription Drugs Advisory Committee organised by the American Cleaning Institute, health professionals and industry safety experts said that active ingredients used in antibacterial hygiene products "clearly save lives" and are recognised as the "standard of care" for reducing healthcare infections.

"A robust body of research supports the safety of active ingredients used in healthcare antiseptic products," wrote the ACI in comments submitted to the NDAC panel. "Any suggestion that the benefit or risk of these products is in question, especially by FDA, could lead to unintended adverse consequences if usage patterns were to change in the healthcare setting."

The FDA is to propose a new set of rules governing antibacterial healthcare hygiene products in 2015.

Previous public announcements made by the FDA - questioning the safety and efficacy of key antibacterial ingredients - have failed to acknowledge the full database of studies and research supporting the ingredients' benefits and safety profiles.

"Healthcare providers need to have a full range of antibacterial actives at their disposal to best meet their infection control needs," said Dr. Paul DeLeo, ACI Associate Vice President, Environmental Safety. "Any effort by FDA that would impede availability of these important ingredients would put patients and healthcare personnel at risk."

Speakers at the ACI-organised presentation urged the Advisory Committee to recommend that the FDA conduct a full risk assessment of currently available health & safety data on antibacterial ingredients.

"The active ingredients used in healthcare antiseptic drug products have a very favourable benefit/risk ratio demonstrated over many years of extensive use," said Dr DeLeo. "These products clearly save lives by reducing bacterial transmission, which can cause infections in healthcare settings. By reducing healthcare-associated infections, these products also reduce healthcare costs."

E: [email protected]
W: www.cleaninginstitute.org

4th September 2014